Going Concern Warning Persists Amidst Highly Dilutive Financing and Nasdaq Listing

summarizeSummary

Lakewood-Amedex Biotherapeutics reported a persistent going concern warning, significant net losses, and a low cash balance, despite completing a highly dilutive $6.8 million Series C financing and Nasdaq listing, which triggered massive share conversions.

check_boxKey Events

• Persistent Going Concern Warning

  Management states that substantial doubt about the company's ability to continue as a going concern has not been alleviated, despite recent financing.

• Significant Net Loss and Low Cash

  Reported a net loss of $0.9 million for Q1 2026 (up from $0.5 million in Q1 2025) and ended the quarter with only $11,709 in cash and cash equivalents.

• Highly Dilutive Series C Financing

  Subsequent to quarter-end, the company completed a private offering of Series C Convertible Preferred Stock, raising $6.8 million in net proceeds. The Series C Preferred Stock has a variable conversion price (80% of lowest closing, min $1.00) and 12% cumulative dividends, indicating unfavorable terms.

• Massive Share Dilution from Conversions

  Upon Nasdaq listing, $1.5 million in convertible notes, all Series A and Series B preferred stock, and $10.6 million in accrued Series B dividends automatically converted into common stock, significantly increasing the outstanding share count.

auto_awesomeAnalysis

Lakewood-Amedex Biotherapeutics continues to face substantial doubt about its ability to continue as a going concern, despite recently securing $6.8 million in net proceeds from a Series C Convertible Preferred Stock offering. This financing, while critical for operations through Q4 2026, comes with highly dilutive terms, including a variable conversion price that can drop to $1.00 per share and 12% cumulative dividends. The company also completed its Nasdaq listing, which triggered the conversion of $1.5 million in convertible notes, Series A and Series B preferred stock, and $10.6 million in accrued Series B dividends into common stock. These conversions and the Series C offering represent a massive increase in the common share count, significantly diluting existing shareholders. Additionally, the company disclosed material weaknesses in its internal controls over financial reporting, adding to governance concerns.